RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.
about
Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical CancerEvaluation of Cancer Dependence and Druggability of PRP4 Kinase Using Cellular, Biochemical, and Structural ApproachesHigh-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesAnalysis of high-throughput RNAi screening data in identifying genes mediating sensitivity to chemotherapeutic drugs: statistical approaches and perspectivesValidation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targetsTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.RNAi screening: new approaches, understandings, and organisms.Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.Three-dimensional in vitro co-culture model of breast tumor using magnetic levitation.Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing.The Cancer BioChip System: a functional genomic assay for anchorage-independent three-dimensional breast cancer cell growth.Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.A polyethylenimine-modified carboxyl-poly(styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-β receptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice.Personalized chemotherapy selection for breast cancer using gene expression profilesTransforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: an update.Recent advances in delivery of drug-nucleic acid combinations for cancer treatmentDiverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.Probenecid is a chemosensitizer in cancer cell lines.The potential RNAi-based combination therapeutics.Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.Inhibition of wild-type p53-induced phosphatase 1 promotes liver regeneration in mice by direct activation of mammalian target of rapamycin.Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.Applications of RNA Indexes for Precision Oncology in Breast Cancer
P2860
Q26799484-6D696CF7-49B4-4D9F-821E-1B5FD1318359Q27679866-7E0C8177-2302-4740-B4C2-78827CB1A69AQ28480861-F8E03B08-DE52-460E-AB9E-2E7E388135D0Q29617680-20E60D86-55CB-45B5-9B4E-7CDCE5D0ACF7Q30583965-85880F39-F9B7-43CC-BE15-06582ACD1C87Q31103913-0E879F84-5221-4AD4-B971-61B550E70EBFQ33769821-27AC3C69-72CC-4D28-8C5D-2E4AE6216C5FQ34033373-DF12B734-50C8-4736-A639-5DD7E6B20877Q34152071-F3513451-07D2-4E0B-83DA-02401486B894Q34270657-CFCAD4D2-AB40-4B71-B149-0AF35DB88528Q34480926-81911D60-F2BE-4D7E-BFD3-79ABA232669CQ36306290-3654721F-489C-400B-8BFC-C9C361D48166Q36544999-CA63E0B7-02D8-4DEE-81C4-FB67F1079B7AQ36638173-8613E83E-83EA-4467-97BD-C4E7AB842666Q37515643-849644FB-9012-4441-BA48-AE666DF1CFEBQ37679039-11143EF5-7DE1-40C7-9C9D-4F601777DB2AQ37918451-FD856AE1-31B1-43C7-A4DE-AB64194B4C95Q38102522-94AC1C70-A7DF-4DC3-BA62-28E6509F88A2Q38768199-65546B57-1C75-4224-9C6C-94BDA099A140Q38833666-2A5E6CD3-2FEC-4FB8-A30A-F6CECEFA08D4Q39025625-058381F9-0046-47CB-A905-7C7E020D3FF4Q39485986-BD9BF275-F5D3-490A-B645-47B9FD0D5209Q39563610-1667439B-F160-4A94-86DA-09F03B722D6DQ41233155-D237CEF9-C8C5-4394-AA32-EE40038EAE68Q42429773-261A3ECC-C6DC-4708-AC2E-9EA8EE0B0980Q51116483-E85E36AE-D37B-4F10-86DB-F658A8531131Q52657603-02002BC2-1B13-49FC-9C39-C57E39291740Q55360028-BBA5CC7B-35B9-4653-8320-B2696D496231Q57113927-E9600EFD-0588-4A61-BC13-58E2A7D80B79
P2860
RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
RNA interference (RNAi) screen ...... tivity in breast cancer cells.
@ast
RNA interference (RNAi) screen ...... tivity in breast cancer cells.
@en
type
label
RNA interference (RNAi) screen ...... tivity in breast cancer cells.
@ast
RNA interference (RNAi) screen ...... tivity in breast cancer cells.
@en
prefLabel
RNA interference (RNAi) screen ...... tivity in breast cancer cells.
@ast
RNA interference (RNAi) screen ...... tivity in breast cancer cells.
@en
P2093
P2860
P356
P1476
RNA interference (RNAi) screen ...... ctivity in breast cancer cells
@en
P2093
Carlos L Arteaga
Christopher S Pendleton
Clayton B Marshall
Joshua A Bauer
P2860
P2888
P356
10.1186/BCR2595
P577
2010-06-24T00:00:00Z
P5875
P6179
1013863574